Park Ha Biological Technology Co., Ltd.
BYAHdata completeness 88%4 fiscal years on fileData notes: no data for concept 'totalDebt'; no data for concept 'interestExpense'
Park Ha Biological Technology Co., Ltd. earns about -4567% on invested capital, below its ~9% cost of capital, and has bought back 98% of its shares over 4 years — no moat visible in the numbers. The estimate methods put fair value between $5.89 and $8.95 a share.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.
| Figure | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Revenue | $1.92M1 | $2.46M2 | $2.38M2 | $2.52M2 |
| Net income | $191,2983 | $852,0424 | $478,5614 | −$24.4M4 |
| Operating cash flow | $1.44M5 | $126,5376 | $960,4706 | $85,8526 |
| Capital expenditure | $11,8907 | $22,6768 | $85,5698 | $88,8258 |
| Free cash flow (derived) | $1.43M5 | $103,8616 | $874,9016 | −$2,9736 |
| Total debt | — | — | — | — |
| Cash & equivalents | $574,7119 | $1.03M10 | $547,49811 | $3.79M11 |
| Diluted shares | 25.0M | 500,000 | 500,000 | 588,866 |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on $67.84 of net worth that earned you −$413.76 and generated −$0.05 of cash last year.
It earned about -4567% on invested capital against a ~9% cost of capital — below the cost of funding. The numbers show no moat.
seeing a moat in the numbers →Share count is down 98% over 4 years — management has been buying back stock, quietly handing owners a bigger slice.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
The 3 estimate methods that apply put fair value between $5.89 and $8.95 a share. They rest on different assumptions, so where they diverge is the story.
assumptions (10)
- riskFreeRate4.7%
- equityRiskPremium5.0%
- beta100.0%
- equityWeight85.0%
- costOfDebtSpread1.5%
- taxRate21.0%
- terminalGrowth2.5%
- projectionYears10
- fcfGrowth0.0%
- fcfBase$103,861
assumptions (10)
- riskFreeRate4.7%
- equityRiskPremium5.0%
- beta100.0%
- equityWeight85.0%
- costOfDebtSpread1.5%
- taxRate21.0%
- terminalGrowth2.5%
- projectionYears5
- fcfGrowth0.0%
- fcfBase$103,861
assumptions (8)
- riskFreeRate4.7%
- equityRiskPremium5.0%
- beta100.0%
- equityWeight85.0%
- costOfDebtSpread1.5%
- taxRate21.0%
- normalizedEarnings$334,929.5
- growthAssumed0.0%
Different models answer different questions — which to trust when →
| Bear | 0.0% | $8.95 |
| Base | 0.0% | $8.95 |
| Bull | 5.0% | $9.56 |
Bear/base/bull growth = 0% / filed history / history + 5pp. Type a price to see the return each case implies.
Default growth 0.0%= this company’s own filed history (median-to-median FCF CAGR, clamped 0–20%). Your adjustments are recorded anonymously. They become the “what do owners actually believe” dataset.
- 20-F · period ending 2022-10-31 · accession 0001213900-25-016603 (Revenues)
- 20-F/A · period ending 2023-10-31 · accession 0001213900-26-057152 (Revenues)
- 20-F · period ending 2022-10-31 · accession 0001213900-25-016603 (NetIncomeLoss)
- 20-F/A · period ending 2023-10-31 · accession 0001213900-26-057152 (NetIncomeLoss)
- 20-F · period ending 2022-10-31 · accession 0001213900-25-016603 (NetCashProvidedByUsedInOperatingActivities)
- 20-F/A · period ending 2023-10-31 · accession 0001213900-26-057152 (NetCashProvidedByUsedInOperatingActivities)
- 20-F · period ending 2022-10-31 · accession 0001213900-25-016603 (PaymentsToAcquireProductiveAssets)
- 20-F/A · period ending 2023-10-31 · accession 0001213900-26-057152 (PaymentsToAcquireProductiveAssets)
- 20-F/A · period ending 2022-10-31 · accession 0001213900-26-057152 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)
- 20-F · period ending 2023-10-31 · accession 0001213900-25-016603 (CashAndCashEquivalentsAtCarryingValue)
- 20-F/A · period ending 2024-10-31 · accession 0001213900-26-057152 (CashAndCashEquivalentsAtCarryingValue)